# Candel Therapeutics

Source: https://onco.cc/companies/candel-therapeutics/  
OnCo record `candel-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Candel makes viral immunotherapies injected into tumours to trigger an immune attack. Its lead product, aglatimagene, improved disease-free survival when added to radiotherapy in localised prostate cancer in a phase 3 trial, and a US approval filing is planned for late 2026.

## Summary

Candel Therapeutics is a Needham, Massachusetts clinical-stage company developing multimodal viral immunotherapies. Lead candidate aglatimagene besadenovec (CAN-2409), an adenoviral immunotherapy, showed a statistically significant improvement in disease-free survival when added to standard radiotherapy in a pivotal phase 3 trial in localised, intermediate- to high-risk prostate cancer (published in The Lancet Oncology); a BLA submission is planned for the fourth quarter of 2026 with a potential US launch in 2027. The global pivotal phase 3 AURORA trial in stage IV non-squamous non-small cell lung cancer progressing on pembrolizumab has opened enrolment. CAN-3110 (linoserpaturev), an HSV-based oncolytic immunotherapy, is being planned for a randomised phase 2 trial in recurrent glioblastoma. Candel had $201.6 million in cash at 30 June 2026 with runway into the first quarter of 2028. Nasdaq: CADL.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Needham, MA
- Type: biotech
- Website: https://candeltx.com/
- Ticker: CADL

## Notes

- No funding round sourced.

## Sources

- Official website: https://candeltx.com/
- Q2 2026 results (8-K exhibit 99.1): https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-ex99_1.htm
- Board appointment noting planned BLA (8-K exhibit 99.1, September 2026): https://www.sec.gov/Archives/edgar/data/1841387/000119312526387310/cadl-ex99_1.htm

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Oncolytic viruses](https://onco.cc/technologies/oncolytic-virus/)
- drugs: [Aglatimagene besadenovec](https://onco.cc/drugs/aglatimagene-besadenovec/)
- trials: [A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec](https://onco.cc/trials/nct07332000/), [Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)](https://onco.cc/trials/aurora/), [CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC](https://onco.cc/trials/nct04495153/), [Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer](https://onco.cc/trials/nct01436968/), [Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)](https://onco.cc/trials/nct02768363/)

---
JSON: https://onco.cc/api/v1/entities/candel-therapeutics.json